arrow
T

Terry J. Fry

national institute of standards and technology
H指数:61
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

为复发/难治性B细胞恶性疾病启用talicabtagene autoleucel的获取途径;关于其配送、有效性和安全性的多中心真实世界证据

2026-07-160
OA
A single-cell multi-omics assay for simultaneous measurement of vector copy number and protein expression in CAR T cells

单细胞多组学方法用于CAR T细胞中载体拷贝数和蛋白质表达的同步测量

2026-05-010
OAAI
10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia

10年CD22 CAR T细胞在儿童和年轻成人B细胞急性淋巴细胞白血病中的应用经验

2025-12-220
OAAI
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL

胸腺基质淋巴细胞生成素受体共靶向以降低CRLF2重排Ph-like型和唐氏综合征ALL的免疫治疗耐药性

BLOOD
IF23.1
2024-11-050
PRE
Two decades of advances in clinical oncology - lessons learned and future directions

临床肿瘤学二十年的进展-经验教训和未来方向

2024-10-011
PRE
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

靶向小胶质细胞中tgf β 活化激酶-1活化可降低CAR T免疫效应细胞相关神经毒性综合征

2024-05-133
PRE
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

嵌合抗原受体T细胞作为嵌合抗原受体后T细胞衰竭的挽救疗法

2023-09-014
OAAI